Electroporation-enhanced delivery of DNA vaccines

BioProcess International

Volumn 9, Issue SUPPL. 8, 2011, Pages 10-14

  Kim, J Joseph ^a  

^a Inovio Pharmaceuuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTHRAX VACCINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HVTN 80; PLASMID DNA; UNCLASSIFIED DRUG; VGX 3100; VIRUS VACCINE;

ANTHRAX; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; ELECTROPORATION; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION;

EID: 84863242677     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (26)

1. Offit PA. Vaccinated. HarperCollins, New York 2007.
2. Weiner DB. DNA Vaccines: Crossing a Line in the Sand. Vaccine 26, 2008: 5073-5074.
3. Donnelly JJ, et al. DNA Vaccines. Annu. Rev. Immunol. 15 1997: 617-648. (Pubitemid 27169294)
4. Listner K, et al. Development of a Highly Productive and Scalable Plasmid DNA Production Platform. Biotechnol. Prog. 22, 2006: 1335-1345. (Pubitemid 44568809)
5. Victoria JG, et al. Viral Nucleic Acids in Live-Attenuated Vaccines: Detection of Minority Variants and an Adventitious Virus. J. Virol. 84, 2010: 6033-6040.
6. Onions D, Kolman J. Massively Parallel Sequencing: A New Method for Detecting Adventitious Agents. Biologicals 38, 2010: 377-380.
7. Cukjati D, et al. Real Time Electroporation Control for Accurate and Safe In Vivo Non-Viral Gene Therapy. Bioelectrochemistry 70, 2007: 501-507. (Pubitemid 46507981)
8. Trollet C, et al. Electrotransfer into Skeletal Muscle for Protein Expression. Curr. Gene Ther. 6, 2006: 561-578. (Pubitemid 44524460)
9. Becker SM, Kuznetsov AV: Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model. J. Biomech. Eng. 129, 2007: 712-721. (Pubitemid 350005833)
10. Hirao LA, et al. Comparative Analysis of Immune Responses Induced By Vaccination with SIV Antigens By Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques. Mol. Ther. 18 2010: 1568-1576.
11. Livingston BD, et al. Comparative Performance of a Licensed Anthrax Vaccine versus Electroporation-based Delivery of a PA Encoding DNA Vaccine in Rhesus Macaques. Vaccine 28 2010: 1056-1061.
12. Hooper JW, et al. Smallpox DNA Vaccine Delivered By Novel Skin Electroporation Device Protects Mice Against Intranasal Poxvirus Challenge. Vaccine 25 2007: 1814-1823. (Pubitemid 46176327)
13. Hirao LA, et al. Multivalent Smallpox DNA Vaccine Delivered By Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge. J. Infect. Dis. 203, 2010: 95-102.
14. Bagarazzi M, et al. Immunotherapy of Post-LEEP CIN2/3 with HPV 16 and 18 E6/E7 DNA Vaccines/Electroporation. 50th ICAAC, Boston, MA. 12-15 September 2010.
15. Trimble CL, et al. A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3. Clin. Cancer Res. 15, 2009: 361-367.
16. Kenter GG, et al. Vaccination Against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. N Engl. J. Med. 361, 2009: 1838-1847.
17. Low L, et al. DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Hum. Gene Ther. 20, 2009: 1269-1278.
18. Dolter KE, et al. Immunogenicity, Safety, Biodistribution, and Persistence of ADVAX: A prophylactic DNA Vaccine for HIV-1 Delivered By In Vivo Electroporation. Vaccine 29, 2010: 795-803.
19. Roos AK, et al. Skin Electroporation: Effects on Transgene Expression, DNA Persistence, and Local Tissue Environment. PLoS One 4, 2009: e7226.
20. Brave A, et al. Induction of HIV-1-Specific Cellular and Humoral Immune Responses following Immunization with HIV-DNA Adjuvanted with Activated Apoptotic Lymphocytes. Vaccine 8, 2010: 2080-2087.
21. Edwith BJ, et al. Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice. Intervirology 43, 2000: 258-272.
22. De Rosa S. Preliminary Results for T Cell Immunogenicity. HIV Vaccines Trial Network; www.hvtn.org/meeting/ppt/may10/2/P3/DeRosa-HVTN073.pdf
23. Kalams S. HVTN 070 Update. HVTN Conference, 15-17 November 2010, Seattle, WA; www.hvtn.org/meeting/nov10.html.
24. Fuchs J. An Immunogenicity Update from a Phase Ib study of rAd35 as a Prime to rAd5 and as a Boost to DNA in Ad5 Seronegative and Seropositive Persons. HVTN Full Group Meeting, 1-3 June 2011, Washington DC; www.hvtn.org/meeting/june2011.html.
25. Elizaga ML. The HVTN Experience with Modified Vaccinia Ankara; www.hvtn.org/meeting/ppt/may08/wedpm/elizaga.ppt-2008-05-21.
26. Vasan S, et al. In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS ONE 6(5) 2011: e19252. Epub 16 May 2011.